CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.

The Danish firm’s four key products yielded 31% sales growth in 2022, and the company is investing in the anticipated mid-year launch of an Alzheimer’s agitation indication for Rexulti.

Private Company Edition: Pitchbook is out with an early look at its venture capital expectations for next year, showing continued interest in seed financings and fewer $100m-plus mega-rounds. Recent VC deals include a $75m series B financing for Alpha-9 Theranostics and $71.6m for A2 Biotherapeutics. 

Already selling at a run rate above $2bn annually, AbbVie predicts the atypical antipsychotic could reach the $4bn mark with a new US indication for adjunctive treatment of major depressive disorder.